Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.

INTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity tha...

Full description

Bibliographic Details
Main Authors: Mark A Ahlman, Davis M Vigneault, Veit Sandfort, Roberto Maass-Moreno, Jenny Dave, Ahmed Sadek, Marissa B Mallek, Mariana A F Selwaness, Peter Herscovitch, Nehal N Mehta, David A Bluemke
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5683610?pdf=render
id doaj-ec51e24d027d400cbc9f72a0a797a73c
record_format Article
spelling doaj-ec51e24d027d400cbc9f72a0a797a73c2020-11-24T21:34:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-011211e018799510.1371/journal.pone.0187995Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.Mark A AhlmanDavis M VigneaultVeit SandfortRoberto Maass-MorenoJenny DaveAhmed SadekMarissa B MallekMariana A F SelwanessPeter HerscovitchNehal N MehtaDavid A BluemkeINTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity that cannot be fully corrected for using typical normalization strategies. The purpose of this study was to evaluate the ability of the current common methods to normalize for blood activity and to investigate alternative methods for more accurate quantification of vascular inflammation. MATERIALS AND METHODS:The relationship between maximum FDG aorta wall activity and mean blood activity was evaluated in 37 prospectively enrolled subjects aged 55 years or more, treated for hyperlipidemia. Target maximum aorta standardized uptake value (SUV) and mean background reference tissue activity (blood, spleen, liver) were recorded. Target-to-background ratios (TBR) and arterial maximum activity minus blood activity were calculated. Multivariable regression was conducted, predicting uptake values based on variation in background reference and target tissue FDG uptake; adjusting for gender, age, lean body mass (LBM), blood glucose, blood pool activity, and glomerular filtration rate (GFR), where appropriate. RESULTS:Blood pool activity was positively associated with maximum artery wall SUV (β = 5.61, P<0.0001) as well as mean liver (β = 6.23, P<0.0001) and spleen SUV (β = 5.20, P<0.0001). Artery wall activity divided by blood activity (TBRBlood) or subtraction of blood activity did not remove the statistically significant relationship to blood activity. Blood pool activity was not related to TBRliver and TBRspleen (β = -0.36, P = NS and β = -0.58, P = NS, respectively). CONCLUSIONS:In otherwise healthy individuals treated for hyperlipidemia, blood FDG activity is associated with artery wall activity. However, variation in blood activity may mask artery wall signal reflective of inflammation, which requires normalization. Blood-based TBR and subtraction do not sufficiently adjust for blood activity. Warranting further investigation, background reference tissues with cellular uptake such as the liver and spleen may better adjust for variation in blood activity to improve assessment of vascular activity.http://europepmc.org/articles/PMC5683610?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Mark A Ahlman
Davis M Vigneault
Veit Sandfort
Roberto Maass-Moreno
Jenny Dave
Ahmed Sadek
Marissa B Mallek
Mariana A F Selwaness
Peter Herscovitch
Nehal N Mehta
David A Bluemke
spellingShingle Mark A Ahlman
Davis M Vigneault
Veit Sandfort
Roberto Maass-Moreno
Jenny Dave
Ahmed Sadek
Marissa B Mallek
Mariana A F Selwaness
Peter Herscovitch
Nehal N Mehta
David A Bluemke
Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
PLoS ONE
author_facet Mark A Ahlman
Davis M Vigneault
Veit Sandfort
Roberto Maass-Moreno
Jenny Dave
Ahmed Sadek
Marissa B Mallek
Mariana A F Selwaness
Peter Herscovitch
Nehal N Mehta
David A Bluemke
author_sort Mark A Ahlman
title Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
title_short Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
title_full Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
title_fullStr Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
title_full_unstemmed Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: Implications for cardiovascular risk stratification and clinical trials.
title_sort internal tissue references for 18fluorodeoxyglucose vascular inflammation imaging: implications for cardiovascular risk stratification and clinical trials.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description INTRODUCTION:18Fluorodeoxyglucose (FDG) positron emission tomography (PET) uptake in the artery wall correlates with active inflammation. However, in part due to the low spatial resolution of PET, variation in the apparent arterial wall signal may be influenced by variation in blood FDG activity that cannot be fully corrected for using typical normalization strategies. The purpose of this study was to evaluate the ability of the current common methods to normalize for blood activity and to investigate alternative methods for more accurate quantification of vascular inflammation. MATERIALS AND METHODS:The relationship between maximum FDG aorta wall activity and mean blood activity was evaluated in 37 prospectively enrolled subjects aged 55 years or more, treated for hyperlipidemia. Target maximum aorta standardized uptake value (SUV) and mean background reference tissue activity (blood, spleen, liver) were recorded. Target-to-background ratios (TBR) and arterial maximum activity minus blood activity were calculated. Multivariable regression was conducted, predicting uptake values based on variation in background reference and target tissue FDG uptake; adjusting for gender, age, lean body mass (LBM), blood glucose, blood pool activity, and glomerular filtration rate (GFR), where appropriate. RESULTS:Blood pool activity was positively associated with maximum artery wall SUV (β = 5.61, P<0.0001) as well as mean liver (β = 6.23, P<0.0001) and spleen SUV (β = 5.20, P<0.0001). Artery wall activity divided by blood activity (TBRBlood) or subtraction of blood activity did not remove the statistically significant relationship to blood activity. Blood pool activity was not related to TBRliver and TBRspleen (β = -0.36, P = NS and β = -0.58, P = NS, respectively). CONCLUSIONS:In otherwise healthy individuals treated for hyperlipidemia, blood FDG activity is associated with artery wall activity. However, variation in blood activity may mask artery wall signal reflective of inflammation, which requires normalization. Blood-based TBR and subtraction do not sufficiently adjust for blood activity. Warranting further investigation, background reference tissues with cellular uptake such as the liver and spleen may better adjust for variation in blood activity to improve assessment of vascular activity.
url http://europepmc.org/articles/PMC5683610?pdf=render
work_keys_str_mv AT markaahlman internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT davismvigneault internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT veitsandfort internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT robertomaassmoreno internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT jennydave internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT ahmedsadek internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT marissabmallek internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT marianaafselwaness internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT peterherscovitch internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT nehalnmehta internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
AT davidabluemke internaltissuereferencesfor18fluorodeoxyglucosevascularinflammationimagingimplicationsforcardiovascularriskstratificationandclinicaltrials
_version_ 1725950175013240832